Why Your Cat's FIP Treatment Just Got Stronger: Dual Antiviral Capsules Explained

How combining GS-441524 and EIDD-1931 in a single daily capsule delivers better virus suppression and lowers resistance risk for cats fighting Feline Infectious Peritonitis (FIP).

Why Your Cat's FIP Treatment Just Got Stronger: Dual Antiviral Capsules Explained

The Case for Dual Antiviral Therapy

If your cat has been diagnosed with Feline Infectious Peritonitis (FIP), you already know that GS-441524 is the most widely used antiviral treatment available. Since 2019, it has helped tens of thousands of cats recover, with success rates of approximately 92% when the full 84-day protocol is completed.

But here is what many cat owners do not know: in human medicine, using a single antiviral drug to treat a serious viral infection has been largely replaced by combination therapy. HIV, hepatitis C, and COVID-19 are all treated with multiple antivirals working through different mechanisms. The reason is that viruses can develop resistance to a single drug over extended treatment periods.

Feline Infectious Peritonitis (FIP) treatment lasts 84 days. That is nearly three months of daily medication, giving the virus opportunities to adapt. CURE FIP™ Dual Antiviral Oral Capsules address this by combining GS-441524 and EIDD-1931, two antivirals with completely different mechanisms, in one capsule.

Two Different Approaches to Stopping the Virus

GS-441524 works by halting viral RNA replication. It gets incorporated into the growing RNA chain and stops the virus from making copies. Published clinical data is extensive: a UC Davis field trial showed 24 of 26 cats achieving sustained remission, a 2025 systematic review of 650 cases reported 84.6% overall success, and a 307-cat retrospective found 84.4% alive at longest follow-up.

EIDD-1931 works by corrupting the copies. Instead of stopping replication, it introduces errors into the virus's genetic code until the viral genome becomes nonfunctional. A Japanese comparative study of 118 cats showed molnupiravir and GS-441524 achieved equivalent remission rates. An Ohio State study confirmed it works as a rescue therapy when GS-441524 alone is insufficient.

Combined: Direct replication block + copy corruption = a dual attack far more effective than either drug alone.

Why Resistance Prevention Matters for Your Cat

Over 84 days, there is always a small probability that the virus mutates in ways that reduce a single drug's effectiveness. With two different mechanisms, the virus would need to develop resistance to both simultaneously. A study of 46 cats using GS-441524 combined with another antiviral achieved 97.8% survival in just four weeks, with zero relapses at 10 months. In neurological Feline Infectious Peritonitis (FIP), combination therapy produced consistently better outcomes.

When Dual Therapy Is Especially Important

Neurological Feline Infectious Peritonitis (FIP). GS-441524 reaches only 7-21% of blood levels in cerebrospinal fluid. A second antiviral mechanism helps compensate.

Incomplete remission. Some cats improve but do not fully recover on one drug.

Relapse prevention. Dual therapy reduces residual viral activity.

Calicivirus co-infection. EIDD-1931 also targets feline calicivirus (FCV).

One Capsule. One Daily Dose. Two Mechanisms.

CURE FIP™ combines both antivirals in a single capsule. No managing two separate medications. A clinical trial at LMU Munich confirmed rapid improvement in 38 of 40 cats with effusive Feline Infectious Peritonitis (FIP).

If your cat has Feline Infectious Peritonitis (FIP), start treatment immediately and maintain it for 84 days. Dual antiviral therapy adds a second layer of protection. Feline Infectious Peritonitis (FIP) is treatable, and recovery is the expected outcome.

Learn more at curefipusa.com. Free consultations available.